Prokem

Quick links to important sections

Prokem

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Prokem

What is Prokem? An Overview

Property Description
Active ingredient Ciprofloxacin
Form Tablet, Solution for infusion, Ophthalmic solution
Pharmacological class Fluoroquinolone Antibiotic
General purpose Resolving systemic bacterial infections
Origin Synthetic (Quinolone derivative)

Prokem: Definition, Class, and Active Ingredient

Prokem is a prescription-only medication classified as a synthetic broad-spectrum antibiotic belonging to the fluoroquinolone pharmacological group. Its core identity is defined by the sole active substance, Ciprofloxacin, which is a quinoline derivative designed to combat specific types of bacterial pathogens.

This drug is entirely a product of chemical synthesis, distinguishing its structure from older, naturally derived antibiotics. Ciprofloxacin is clinically recognized for its effectiveness against a wide range of susceptible organisms. The drug is engineered to eliminate the bacteria causing infection, a characteristic supported by decades of pharmacological study.


Form, Action, and General Purpose

Prokem is manufactured in several distinct pharmaceutical preparations to ensure effective delivery, including the standard oral tablet, a sterile solution for infusion for intravenous administration, and specialized ophthalmic solutions for local use. This versatility allows the medication to be administered either systemically for widespread issues or applied topically where required.

The general purpose of Prokem is to resolve systemic infections by employing a bactericidal effect. This means the active substance works by actively killing the bacterial cells rather than merely halting their reproduction. This definitive action targets the root cause of the infection, providing a mechanism for the body to achieve rapid bacterial clearance and recovery.

Regulatory References

  1. Ciprofloxacin (Oral Route)

What side effects are possible with Prokem?

Possible Side Effects and Safety Information

The safety profile for Prokem (Ciprofloxacin), a fluoroquinolone antibiotic, is comprehensively documented in regulatory sources such as the FDA Prescribing Information and the EMA Summary of Product Characteristics. This information details adverse reactions by frequency, the organ systems affected, and significant safety restrictions.

Frequency-Classified Adverse Reactions

Adverse reactions are categorized based on their official likelihood of occurrence:

Classification Examples of Documented Reactions
Common (1 in 100 to 1 in 10) Nausea, Diarrhoea
Uncommon (1 in 1,000 to 1 in 100) Headache, Dizziness, Vomiting, Skin rash, Increased liver enzymes (transaminases)
Rare (1 in 10,000 to 1 in 1,000) Tendinitis, Tendon rupture, Seizures, Allergic reactions
Frequency Not Known Peripheral neuropathy, Aortic Aneurysm, Aortic Dissection

Serious Safety Warnings and Restrictions

The regulatory profile highlights serious, potentially disabling, and irreversible reactions, often affecting the Musculoskeletal and Nervous Systems. These include tendon rupture, peripheral neuropathy, and significant central nervous system effects such as confusion and psychoses.

Specific safety constraints are mandated in official labeling:

  • Contraindications: Use is restricted in individuals with a known history of hypersensitivity to quinolone antibiotics or pre-existing Myasthenia Gravis.
  • Population-Specific Notes: Older adults face an officially increased risk of severe tendon disorders. Specific warnings regarding tendon issues also apply to the pediatric population. Dosage adjustment is required for patients with documented renal impairment.
  • Time-Related Patterns: Serious reactions, including neurological effects, may occur after the first dose. Tendon rupture can be a delayed reaction, occurring months after discontinuing the medication.

Overdose and Emergency Response

Overdose and when to seek help

Category Official Regulatory Statements for Prokem (Ciprofloxacin)
Documented overdose presentations: Reversible renal toxicity; crystalluria (crystals in the urine) has been reported.
Physiological systems affected: Renal system.
Emergency-response statements: Employ procedures to empty the stomach; maintain adequate hydration; administer activated charcoal or antacids to reduce absorption; manage symptoms.
When immediate medical help is required: Seek immediate medical attention upon known or suspected acute overdose.

Overdose Classifications

Category Official Regulatory Classification/Basis
Severity classification: Potential for acute outcomes, specifically acute renal failure.
Overdose-context constraints: Management is supportive and symptomatic, as no specific antidote is known.

Resulting Overdose Structure

Official overdose statements:

  • Overdose may present with reversible renal toxicity and the formation of crystalluria, which holds the potential to progress to acute renal failure.
  • Immediate medical attention must be sought for any known or suspected acute overdose, as no specific antidote is known.
  • Procedural steps include emptying the stomach and using agents like activated charcoal to reduce absorption.
  • Adequate hydration must be maintained, and close monitoring of renal function and urinary pH is required.
  • Management is complicated by the fact that only a small amount (less than 10%) of the drug is removed by hemodialysis or peritoneal dialysis.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the Prokem overdose profile based primarily on the potential for kidney-related toxicity and the need for immediate, supportive management. The official guidance mandates that patients seek immediate medical attention to initiate monitoring and procedural interventions—such as hydration and renal function checks—to mitigate the serious risk of acute renal failure. This approach is necessitated because there is no specific antidote listed in the official labeling.

Therapeutic Uses of Prokem

What Prokem Treats: Main Uses and Benefits

Prokem's key purpose is to offer supportive relief across various symptomatic domains, focusing on managing discomfort, assisting with functional stability, and contributing to easing day-to-day comfort during periods of heightened patient distress. This approach to symptom management aligns with the general therapeutic uses of its class.


Managing Symptom Clusters and Functional Strain

Prokem is commonly used to address symptom clusters that may become intense or disruptive, such as those related to physical discomfort, symptoms of increased neurological or muscular activity, and symptoms that create noticeable physiological strain. It is considered relevant in clinical settings where supportive symptom management is appropriate, provides support that helps ease the overall symptom burden, and contributes to easing day-to-day comfort during difficult episodes.

The medication may be applied in conditions characterized by symptoms that are episodic or fluctuating, often involving periods of increased physiological tension. In such scenarios, it may be part of symptomatic management that assists with short-term symptom stabilization. It assists with addressing symptom groups that require supportive management, and may assist patients with coping more steadily when symptoms are more noticeable.


Quick Fact Block

Quick Fact: Support for Symptoms that interfere with daily functioning

Eligibility and Restrictions for Use

Official Population Eligibility and Restrictions

Prokem’s eligibility is strictly defined by regulatory classifications, establishing specific non-eligibility rules and conditional use criteria for certain populations. This information is based solely on governmental labeling and contraindication sections.

Absolute Contraindications (Must Not Use):

  • Known allergy or hypersensitivity to ciprofloxacin or any other quinolone antibiotic.
  • Concomitant use with the drug tizanidine.
  • Known history of Myasthenia Gravis, as use may exacerbate muscle weakness.

Age and Life Stage Rules: Adults are the standard approved population for Prokem. Use in pediatric patients is generally restricted and reserved for specific, severe infections when alternative options are deemed unsuitable. Use during pregnancy is not established, and it is not recommended for women who are breastfeeding.

Conditional Use and Restrictions: Eligibility is conditional on specific health factors. Caution is required for older adults (60 years), patients with renal impairment (often requiring adjusted use), and those with a history of certain tendon disorders or risk factors for aortic aneurysm or QT interval prolongation. Use is also restricted in patients taking systemic corticosteroids.

What should I know about interactions with other medicines?

Interaction scope

Medicinal product categories with documented interactions: Multivalent Cation-Containing Products (antacids, iron, zinc), CYP1A2 Substrates (Theophylline, Caffeine), QT-Prolonging Agents, NSAIDs, Corticosteroids, Antidiabetic Agents, and Uricosuric Agents (Probenecid).

Specific interacting medicines (if explicitly listed): Tizanidine, Fezolinetant, Flibanserin, Theophylline, Warfarin, Probenecid, Omeprazole, Sucralfate.

Mechanistic basis of interactions (only if stated in label): The principal mechanisms documented are Inhibition of Cytochrome P450 1A2 (reducing clearance of co-administered drugs), Chelation with multivalent cations (reducing absorption), and Additive Pharmacodynamic Effects (e.g., QT interval prolongation).

Timing-based interaction rules (if applicable): The oral form must be separated by at least 2 hours before or 6 hours after multivalent cation-containing products. Dairy products or calcium-fortified juices should not be taken alone.

Population-specific interaction notes (if applicable): The risk of severe tendon disorders from the interaction with Corticosteroids is noted to be increased in geriatric patients.

Interaction-related restrictions: The concomitant use of Tizanidine, Fezolinetant, and Flibanserin is formally classified as contraindicated in the prescribing information.

Interaction classifications (high-level)

Interaction severity classification (as defined in official documents): Contraindicated (Tizanidine, etc.), Major/High Risk (Chelation agents, Theophylline, QT-prolonging drugs).

Regulatory basis (EMA / FDA / etc.): All statements are based on official government regulatory documents (e.g., FDA Prescribing Information and EMA SmPC).

Interaction-context constraints (as defined in official documents): A mandatory time separation window is imposed to mitigate the absorption reduction caused by chelation, and a restriction is placed on taking the product with dairy products alone.

Resulting interaction structure

Official interaction statements:

  • The use of Prokem with Tizanidine is contraindicated because Prokem, as a CYP1A2 inhibitor, increases Tizanidine's concentration and effect.
  • Chelation with multivalent cations significantly reduces Prokem's absorption, requiring a time separation of at least 2 hours before or 6 hours after the cation-containing product.
  • The pharmacodynamic interaction with Corticosteroids increases the risk of tendon disorders, a risk heightened in geriatric patients.

Connection to the overall interaction profile (2–4 sentences): Regulatory documents define the product's interaction structure primarily through two constraints: a pharmacokinetic limitation due to both CYP1A2 inhibition and chelation-based absorption interference, and a critical pharmacodynamic constraint involving the additive risk of QT prolongation. These official classifications detail which combinations are contraindicated and which require strict administration rules to maintain efficacy and safety.

Mechanism of Action

Molecular Targeting: Enzyme Poisoning and DNA Integrity

The core mechanism of Prokem, whose active ingredient is Ciprofloxacin, is its targeted action against two enzymes essential for bacterial survival: DNA Gyrase (Topoisomerase II) and Topoisomerase IV. The drug acts as an enzyme poison, binding to and stabilizing the transient complex formed when these enzymes cleave the bacterial DNA. This prevents the enzymes from resealing the breaks, locking them into a damaged state. This interaction initiates the sequence of events that disrupts the bacterial cell's vital processes.

Mechanistic Cascade: Irreversible Genomic Damage and Bactericidal Action

The stabilization of the drug-enzyme-DNA complex leads directly to the accumulation of irreparable double-strand breaks (DSBs) across the bacterial genome. This unrecoverable genetic damage immediately triggers bacterial cell death (bactericidal action) and the clearance of the susceptible pathogenic population. The mechanistic cascade leads to the physiological consequence of reducing the bacterial load within the system.

Mechanism Limitation: Resistance and Target Evasion

The mechanism is physiologically constrained when bacteria develop counter-mechanisms, primarily through mutations in the target enzyme genes ( gyrA/gyrB or parC/parE) which reduce Ciprofloxacin’s binding affinity, or through the activation of efflux pumps. These pumps actively transport the drug out of the cell, preventing it from reaching the necessary intracellular concentration to poison the molecular targets and initiate the lethal cascade.

Dosage and Administration Information

How Prokem is Used: Official Administration Guidelines

Prokem, which contains Ciprofloxacin, is a medicine with standardized administration protocols. It is officially available for Oral use (immediate- and extended-release tablets), Intravenous (IV) infusion, and Topical ophthalmic application.

Use Parameter Official Administration Rules
Dosing Frequency The standard frequency for most oral immediate-release and IV regimens is twice daily (every 12 hours). The extended-release oral tablet is officially dosed once daily.
Dosing Range Adult oral doses typically range from 250 mg to 750 mg per administration. IV doses typically range from 200 mg to 400 mg per administration, with the maximum dose dependent on the severity and site of infection.
Administration Context Oral tablets may be taken with or without food. However, absorption requires that the dose be separated from supplements or antacids containing multivalent cations (e.g., iron, zinc, calcium) by at least 2 hours before or 6 hours after the dose.
Procedural Steps IV infusion must be administered slowly over 60 minutes. Oral extended-release tablets must be swallowed whole and must not be cut or crushed. Adequate fluid intake is instructed during oral therapy.
Special Populations Dose adjustment is required for adult patients with officially determined reduced kidney function (creatinine clearance < 50 mL/min), often involving a dose reduction or prolonged interval. For pediatric patients, dosing is calculated based on body weight (mg/kg) for specific, approved uses.

These official instructions establish that the route, dosage, frequency, and duration of Prokem use are predefined and cannot be varied, except for mandatory adjustments concerning the patient’s renal status. This structured protocol ensures the medicine is administered according to a standardized framework.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Prokem

Evidence for Use in Complicated Urinary Tract Infections and Pyelonephritis

Research for complicated urinary tract infections, including pyelonephritis (kidney infection), relies primarily on short-term Randomized Controlled Trials (RCTs). These studies were used in research exploring how patient symptoms changed and were focused on determining the clearance of the specific bacteria, known as bacteriologic eradication. Findings describe patterns observed in the studies related to both clinical response and the elimination of the pathogen. Some research has explored whether certain dosing durations reported comparable patterns of bacteriologic eradication for specific bacteria in defined patient groups. The measurements of bacteriologic eradication in studies appear to be influenced by the prevalence of local bacterial resistance.


Evidence for Use in Bone and Joint Infections

Prokem was studied for use in conditions associated with acute or disruptive episodes in the bone and joints, such as osteomyelitis. Research examined both RCTs and observational cohort studies over defined time intervals. These studies explored outcomes related to physical discomfort and the elimination of the bacteria from the deep tissue. Findings describe patterns observed in the studies, where oral Prokem was evaluated for use as part of a prolonged treatment regimen following initial intravenous therapy. Research described patterns of infection resolution that were comparable to those observed following traditional intravenous-only protocols. However, the outcomes are often dependent on whether the patient also received surgical intervention, and evidence quality varies across the diverse types of infection studied.


Evidence for Use in Select Rare/Critical Infections (e.g., Anthrax) ️

For certain rare, life-threatening conditions, direct human efficacy trials are not feasible. Therefore, the evidence base relies heavily on a unique mechanism: animal model studies to measure survival, complemented by human pharmacokinetic (PK) studies. These human studies monitored the drug concentrations achieved in adult and pediatric volunteers. The evidence contributes to understanding the drug levels necessary for the desired effect, based on extrapolation from the animal data. Direct human clinical efficacy data are not available, and certainty remains low regarding the correlation between blood concentration and clinical outcomes.


What is Still Uncertain About Prokem’s Evidence Base

Research highlights areas where data remains limited. For all indications, long-term effects are not fully established regarding the durability of response over many years following treatment. The global increase in bacterial resistance means that evidence quality varies across studies depending on the region and time of conduct. Furthermore, for complicated intra-abdominal infections, Prokem was typically observed as part of a combination regimen, making it challenging to isolate the specific contribution of Prokem alone. In special patient groups, such as children, use is generally reserved for severe infections, and evidence for specific patient subgroups remains insufficient.

Key Studies & References

  1. Ciprofloxacin - StatPearls - NCBI Bookshelf - NIH (Clinical/Regulatory Overview)
  2. Fluoroquinolones for Intra-Abdominal Infections: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines - NCBI (cIAI Review)

Frequently Asked Questions (FAQ)

Common questions about Prokem (FAQ)


Q: Do I need to change my diet while taking Prokem?

Official product information describes that Prokem can be taken either with food or on an empty stomach. The administration instructions note the need to separate the dose from supplements or antacids that contain multivalent cations, such as iron, zinc, or calcium. This timing separation is necessary because those mineral ions can bind to the medicine and reduce how much the body absorbs.


Q: Is Prokem safe to take with common over-the-counter pain relievers?

Official documents indicate that a category of pain relievers called NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), which includes many common over-the-counter products, has documented interactions with Prokem. This combination may increase the risk of certain effects related to the central nervous system.


Q: How quickly should someone expect to notice the effects of Prokem?

Studies and official information indicate that Prokem begins its bactericidal action within a few hours of administration. For most infections, clinical response is typically observed within a timeframe of 2 to 3 days. For more serious, deep-tissue infections, findings suggest the timeframe for clinical response may extend up to a week.


Q: What is the longest period of time Prokem has been studied in clinical trials?

The clinical trials for Prokem, especially those for common infections, rely on short-term data, often lasting between 3 and 14 days. The long-term effects regarding the safety and durability of the response over many years are not fully established in regulatory research.


Q: Is it true that Prokem causes a metallic taste?

The specific side effect of a metallic taste is not noted in official documents for the oral form of Prokem. However, a related formulation for eye use has listed a "bad taste" following the application as a less common adverse reaction.


Q: Can Prokem be taken by older adults?

Prokem is approved for use in adults, including the older adult population. It is noted in regulatory warnings that individuals in this age group face an officially increased risk of severe tendon disorders. This increased risk is a critical safety constraint detailed in official labeling.


Q: If I miss a dose of Prokem, what are the general instructions?

Official patient information provides non-individualized guidance outlining a protocol for a missed dose of the twice-daily tablet. This guidance states that if the next scheduled dose is 6 hours or more away, the missed dose is generally taken immediately. If it is less than 6 hours until the next dose, the protocol is to skip the missed dose and continue with the regular schedule, avoiding a double dose.


Q: Why does the official leaflet mention a warning about heart rhythm changes with Prokem?

The warning is associated with a possible electrical change in the heart known as QT interval prolongation. This change, which is described in official documents, may be linked to an irregular heart rhythm. Prokem is known to interact with other medications that can also prolong the QT interval.


Q: Does Prokem affect sleep patterns?

Official regulatory documents list adverse reactions related to the Central Nervous System (CNS), which could potentially influence sleep. These documented CNS effects include, but are not limited to, dizziness, confusion, and seizures.


Q: Is Prokem considered a controlled substance?

Prokem is legally classified as a prescription-only medication, meaning it requires a prescription from a licensed healthcare professional for dispensing. It is not listed as a federally controlled substance in the United States.


Q: Does Prokem affect birth control pills?

Official patient resources indicate that Prokem does not directly interfere with the action of hormonal contraception, such as birth control pills or implants. However, the regulatory information notes that if the antibiotic causes severe vomiting or diarrhea, this may potentially affect the absorption of the pill.


Q: How long does Prokem typically stay in the body after the last dose?

For individuals with normal kidney function, the serum elimination half-life of Prokem is about 4 hours. Official pharmacology data indicates that it typically takes approximately 20 to 24 hours after the final dose for the medication to be virtually eliminated from the body's system.


Q: Is there a generic version of Prokem available?

Yes, the active ingredient in Prokem, known as Ciprofloxacin, is available in a generic version. This is standard for medications whose regulatory exclusivity period has expired.


Q: Is Prokem associated with any eye problems?

Official documentation confirms that Prokem is associated with some effects on the eyes. The oral form has been linked to visual disturbances. The ophthalmic (eye drop) form commonly lists reactions like ocular discomfort or crusting, and less commonly, blurred vision or dry eye.


Q: Does taking Prokem interfere with laboratory blood tests?

Official regulatory texts do not contain a general warning about interfering with laboratory tests. However, the documented effects of the medicine include a potential increase in liver enzymes (transaminases), which may appear on a routine blood test. It can also mildly elevate results in some urine protein tests.


Q: What is the typical timeframe for a doctor to review if Prokem is working?

Regulatory guidelines do not provide a mandated timeframe for every patient review. However, clinical guidance for complicated infections describes that reassessment is typically initiated within seven days. Furthermore, a healthcare provider may initiate a review or re-culture after 3 to 5 days if there is no observed improvement, such as a persistent fever.


Q: Does Prokem have an interaction with alcohol, as described in official documents?

Official regulatory documents do not include an explicit warning that outright prohibits moderate alcohol consumption while taking Prokem. However, regulatory texts describe that alcohol may increase the severity of certain side effects, such as nausea and drowsiness.


Q: Is it safe to drive or operate machinery while taking Prokem?

The official label advises that certain side effects may affect a person's ability to safely operate a vehicle or machinery. Therefore, the label states that driving should be avoided if a person experiences central nervous system (CNS) effects such as dizziness, lightheadedness, or unsteadiness.


Q: How common are serious side effects from Prokem?

Serious adverse reactions, such as tendon rupture or seizures, are generally classified as Rare in official documents, meaning they affect between 1 in 1,000 and 1 in 10,000 users. Some other serious effects, like peripheral neuropathy, are listed in the category of Frequency Not Known.


Q: Are there any requirements for regular monitoring while taking Prokem?

Regulatory documents describe the need for monitoring kidney function for any patients with pre-existing impairment, which is related to the need for a dosage adjustment. Furthermore, for those undergoing prolonged treatment, monitoring of certain blood cell counts and metabolic panels is often utilized to assess for the presence of adverse effects.


Q: Why do some users report that Prokem feels less effective after several months?

Official regulatory texts describe that a cause of reduced effectiveness is the development of bacterial resistance. This happens when bacteria acquire counter-mechanisms, such as activating efflux pumps, which actively transport the medicine out of the cell. This action prevents the drug from reaching the effective levels needed to eliminate the infection.


Q: Can Prokem affect mood or cause emotional changes?

Official documentation lists central nervous system (CNS) and psychological effects that can potentially influence emotional state. These reactions include confusion, anxiety, and acute psychosis, as well as documented mood changes.


Q: Is Prokem a maintenance medicine or a short-term treatment?

Prokem is classified as a short-term treatment, not a maintenance medicine. The precise duration of therapy is explicitly defined by regulatory guidelines based on the specific type of infection being addressed, typically lasting for a period of days or weeks.


Q: Does Prokem interact with herbal supplements like St. John's Wort?

Official interaction literature suggests that the active ingredient in Prokem may interact with the herbal supplement St. John's Wort. This interaction may reduce the concentration of the herbal supplement in the body.


Q: What are the main conditions that Prokem is officially indicated to treat?

Official regulatory documents list a range of approved indications, or main uses, for Prokem. These include treating certain types of complicated urinary tract infections (UTI), as well as infections in the lower respiratory tract, skin and skin structure, and bone and joints. It is also indicated for specific critical uses, such as post-exposure inhalation anthrax.


Q: What does 'contraindication' mean in the context of Prokem?

A contraindication is a mandatory rule in regulatory documents indicating that a medicine must not be used when a specific condition or circumstance is present. For Prokem, examples include a known allergy to the drug or its simultaneous use with another medicine called Tizanidine. In these situations, the potential for serious harm is considered to outweigh any potential benefit.


Q: How is the long-term safety profile of Prokem described in regulatory documents?

Because Prokem is intended as a short-term treatment, research on its safety profile over many years is limited. Official documents note that serious reactions, such as tendon rupture or peripheral neuropathy, may be disabling and potentially irreversible. Importantly, some of these effects have been documented to occur months after a patient has stopped taking the medication.


Q: What is the purpose of taking Prokem daily?

The purpose of the daily regimen is to maintain a drug concentration in the body that is high enough to effectively kill the target bacteria over the course of the treatment. This consistent level is necessary to sustain the medicine’s bactericidal effect and to help prevent the development of bacterial resistance.


Q: Are there any documented interactions between Prokem and grapefruit?

No official regulatory label explicitly lists grapefruit or grapefruit juice as a prohibited interaction for Prokem. While some research has suggested a theoretical possibility of interference with the drug's metabolism, it is not consistently documented as a mandatory regulatory restriction.


Q: What is the typical expected duration of action for a single dose of Prokem?

The duration of action for a single dose is closely tied to its half-life, which is approximately 4 hours in most individuals. The medicine is typically dosed every 12 hours to maintain drug levels that are consistently in the therapeutic range needed to fight the infection effectively.

How should Prokem be stored and disposed of?

The official regulatory guidelines dictate specific requirements for storing and disposing of Prokem (Ciprofloxacin) based on the medication's form.

Storage and Handling Requirements

  • Temperature Control: Prokem tablets must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), with excursions up to 30 C permitted. The oral liquid must not be frozen.
  • Environmental Protection: The medicine must be protected from light and stored in its tightly closed container to prevent moisture damage.
  • Child Safety: All forms of Prokem must be stored out of the sight and reach of children.

Stability and Disposal Rules

Once the Oral Suspension is mixed, it has a stability period of 14 days and any unused portion must be discarded after this time. For disposal, patients must consult a pharmacist or healthcare provider for instructions on unused or expired medicine. The product must not be disposed of via the sewage system or household garbage, following environmental precaution guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Prokem found in:

A-Z Index: